The assay’s unique design allows it to assess a broad range of biomarkers across > 6 common solid tumor types in blood samples, including SNVs, Indels, CNVs, Fusions and MSI in a single DNA-only, streamlined and robust lab-to-report NGS workflow. It contains 32 genes with > 80% of all ESCAT Level I genes included to date in the ESMO guidelines.
- Panel size: 90 kb
- Instruments supported: Illumina NextSeq and NovaSeq Series
- Multiplexing: up to 6 samples on a NextSeq 500/550 instrument (MID Output flow cell)
- Sample size: min 5 mL plasma required (cfDNA BCT tubes by Streck recommended for blood collection)
- cfDNA input: min 10 ng cfDNA, 30 ng cfDNA recommended
- Library preparation method: Hybrid-capture chemistry
- UMI/UDI technologies: allowing error correction and preventing index hoping for enhanced sensitivity and specificity
